Will Augmentin (amoxicillin‑clavulanate) treat a Pantoea agglomerans infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Will Augmentin Treat Pantoea agglomerans?

Yes, Augmentin (amoxicillin-clavulanate) can treat Pantoea agglomerans infections, though clinical response may be variable and treatment failure has been documented. The evidence shows both successful and unsuccessful outcomes with this antibiotic for this pathogen.

Clinical Evidence for Augmentin in P. agglomerans

The available case reports demonstrate mixed results:

  • Treatment failure documented: One case report describes a patient with P. agglomerans wound infection following plant injury who was initially treated with amoxicillin-clavulanic acid without improvement 1. The infection only resolved after spontaneous release of a retained plant fragment and switching to cotrimoxazole 1.

  • Successful treatment reported: In hemodialysis patients with P. agglomerans infection, most patients responded well to intravenous antibiotics (though specific agents weren't detailed), with only 2 of 17 patients requiring catheter removal and 0% mortality 2.

Key Clinical Considerations

When Augmentin May Fail

The primary reason for treatment failure with Augmentin in P. agglomerans infections is retained foreign material, particularly plant fragments 1. If the infection follows penetrating plant injury:

  • Carefully examine for retained vegetal material
  • Consider imaging if foreign body suspected
  • Surgical removal of foreign material may be necessary for cure
  • Antibiotic therapy alone is insufficient without source control

Antibiotic Susceptibility

P. agglomerans is generally susceptible to multiple antibiotic classes, but local resistance patterns vary. The organism typically responds to:

  • Beta-lactam/beta-lactamase inhibitor combinations (like Augmentin)
  • Fluoroquinolones
  • Trimethoprim-sulfamethoxazole (cotrimoxazole)
  • Third-generation cephalosporins

Dosing Recommendations

If using Augmentin for P. agglomerans:

  • Adults: 875/125 mg orally twice daily 3
  • Duration: 10-14 days for soft tissue infections
  • Consider intravenous formulation (ampicillin-sulbactam) for severe infections or bacteremia

Alternative Approaches

If Augmentin fails or is contraindicated:

  1. First alternative: Trimethoprim-sulfamethoxazole (cotrimoxazole) - demonstrated success in the treatment failure case 1
  2. For severe infections: Third-generation cephalosporins or fluoroquinolones
  3. Always: Ensure adequate source control, especially removal of foreign bodies

Critical Pitfalls

  • Do not rely on antibiotics alone if foreign material is present - this is the most common cause of treatment failure
  • Monitor for device-related infections in patients with indwelling catheters or ports 4
  • Consider environmental exposure - P. agglomerans is plant-associated and infections often follow thorn injuries or plant trauma
  • Obtain cultures when possible to confirm susceptibility, as resistance patterns can vary

Bottom Line

Augmentin is a reasonable empiric choice for P. agglomerans infections, but success depends critically on adequate source control. If the patient fails to improve within 48-72 hours, aggressively search for retained foreign material and consider switching to cotrimoxazole or a fluoroquinolone based on culture results.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.